RT Journal Article
SR Electronic
T1 African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.20.20072926
DO 10.1101/2020.04.20.20072926
A1 Karunamuni, Roshan
A1 Huynh-Le, Minh-Phuong
A1 Fan, Chun
A1 Thompson, Wesley
A1 Eeles, Rosalind
A1 Kote-Jarai, Zsofia
A1 Muir, Kenneth
A1 UKGPCS collaborators
A1 Lophatananon, Artitaya
A1 Tangen, Catherine
A1 Goodman, Phyllis
A1 Thompson, Ian
A1 Blot, William
A1 Zheng, Wei
A1 Kibel, Adam
A1 Drake, Bettina
A1 Cussenot, Olivier
A1 Cancel-Tassin, Geraldine
A1 Menegaux, Florence
A1 Truong, Therese
A1 Park, Jong
A1 Lin, Hui-Yi
A1 Bensen, Jeannette
A1 Fontham, Elizabeth
A1 Mohler, James
A1 Taylor, Jack
A1 Multigner, Luc
A1 Blanchet, Pascal
A1 Brureau, Laurent
A1 Romana, Marc
A1 Leach, Robin
A1 John, Esther
A1 Fowke, Jay
A1 Bush, William
A1 Aldrich, Melinda
A1 Crawford, Dana
A1 Srivastava, Shiv
A1 Cullen, Jennifer
A1 Petrovics, Gyorgy
A1 Parent, Marie-Elise
A1 Hu, Jennifer
A1 Sanderson, Maureen
A1 Mills, Ian
A1 Andreassen, Ole
A1 Dale, Anders
A1 Seibert, Tyler M
A1 The PRACTICAL Consortium
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.20.20072926.abstract
AB Introduction Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46), showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify SNPs that might improve performance in this population.Material and Methods Anonymized genotypic data were obtained from the PRACTICAL consortium for 6,253 men with African genetic ancestry. Ten iterations of a ten-fold cross-validation search were conducted, to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African were compared using the same cross-validated approach.Results Three SNPs (rs76229939, rs74421890, and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47 to 4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65 to 0.53).Conclusions We identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans and Asians. A strategy of building on established statistical models might benefit ancestral groups generally under-represented in genome-wide association studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received in support of the work presented.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, Readers who are interested in accessing the data must first submit a proposal to the Data Access Committee. If the reader is not a member of the consortium, their concept form must be sponsored by a principal investigator (PI) of one of the PRACTICAL consortium member studies. If approved by the Data Access Committee, PIs within the consortium, each of whom retains ownership of their data submitted to the consortium, can then choose to participate in the specific proposal. In addition, portions of the data are available for request from dbGaP (database of Genotypes and Phenotypes) which is maintained by the National Center for Biotechnology Information (NCBI): https://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostatehttps://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostate. Anyone can apply to join the consortium. The eligibility requirements are listed here: http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee access, as a proposal for access would still be submitted to the Data Access Committee, but there would be no need for a separate member sponsor. Readers may find information about application by using the contact information below: Rosalind Eeles Principal Investigator for PRACTICAL Professor of Oncogenetics Institute of Cancer Research (ICR) Sutton, UK Email: PRACTICAL@icr.ac.uk URL: http://practical.icr.ac.uk Tel: ++44 (0)20 8722 4094